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ABSTRACT
The potency and specificity of locked nucleic acid
(LNA) antisense oligonucleotides was investigated
as a function of length and affinity. The oligonucleo-
tides were designed to target apolipoprotein B
(apoB) and were investigated both in vitro and
in vivo. The high affinity of LNA enabled the design
of short antisense oligonucleotides (12- to 13-mers)
that possessed high affinity and increased potency
both in vitro and in vivo compared to longer oligo-
nucleotides. The short LNA oligonucleotides were
more target specific, and they exhibited the same
biodistribution and tissue half-life as longer oligo-
nucleotides. Pharmacology studies in both mice
and non-human primates were conducted with a
13-mer LNA oligonucleotide against apoB, and
the data showed that repeated dosing of the
13-mer at 1–2mg/kg/week was sufficient to
provide a significant and long lasting lowering of
non-high-density lipoprotein (non-HDL) cholesterol
without increasing serum liver toxicity markers.
The data presented here show that oligonucleotide
length as a parameter needs to be considered in the
design of antisense oligonucleotide and that potent
short oligonucleotides with sufficient target affinity
can be generated using the LNA chemistry.
Conclusively, we present a 13-mer LNA oligonucleo-
tide with therapeutic potential that produce benefi-
cial cholesterol lowering effect in non-human
primates.
INTRODUCTION
Potency and speciﬁcity are two key parameters for any
antisense oligonucleotide. Other things being equal,
potency has until now been considered positively
correlated to the aﬃnity of the antisense oligonucleotide
for its target sequence (1,2). Speciﬁcity however is aﬀected
by two somewhat conﬂicting properties. First, the anti-
sense oligonucleotide needs to be long enough in order
to ensure that its target sequence is unique in the tran-
scriptome. Second, as the antisense oligonucleotide is
elongated, its ability to discriminate between the
matched and mismatched sequences, i.e. its intrinsic spe-
ciﬁcity, is diminished. Thus, for optimal speciﬁcity, anti-
sense oligonucleotides should be as short as possible, but
long enough to maintain speciﬁcity for the target. In the
annotated human transcriptome, this requirement can
often be fulﬁlled with oligonucleotides as short as 12- or
13-mers. Despite this, such short oligonucleotides have so
far not been preferred in the antisense ﬁeld, and oligo-
nucleotides in the size range of 18–22nt have traditionally
been used. This size preference is a consequence of the
modest aﬃnity properties of the ﬁrst and second gener-
ation chemical modiﬁcations [e.g. phosphorothioate,
20-O-methyl and 20-O-methoxyethyl (MOE)] that do not
enable suﬃcient target aﬃnity for very short oligonucleo-
tides to exhibit potent pharmacological activity.
Antisense oligonucleotides and siRNAs have recently
been used to target apolipoprotein B-100 (apoB-100;
3–6), and an 20-mer 20-MOE antisense oligonucleotide is
currently in clinical phase 3 trial (7). Thus, in addition to
its potential for being a therapeutically relevant target for
a new class of therapeutics, apoB is also a convenient
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classes of antisense oligonucleotides.
The majority of apoB is synthesized in the liver, where
its constitutive expression results in the production and
secretion of very low-density lipoprotein (VLDL) particles
in response to the hepatic lipid content. In plasma, a
fraction of VLDL is metabolized to low-density lipopro-
tein (LDL) (8). Elevated levels of plasma LDL-cholesterol
is known to be a major risk factor for atherosclerosis,
which in turn is the main underlying cause of coronary
heart disease and stroke (9). Given the relationship
between the hepatic apoB expression, hepatic VLDL se-
cretion and plasma LDL levels, inhibition of apoB mRNA
will lead to a reduction of plasma LDL-cholesterol levels.
In this study, we demonstrate that the high aﬃnity of
locked nucleic acid (LNA; 10,11) can be used to construct
very short oligonucleotides with high pharmacological
activity. We investigate how such size reduction aﬀects
key drug parameters such as speciﬁcity, potency,
biodistribution and tissue half-life.
MATERIALS AND METHODS
Design and synthesis of LNA oligonucleotides
A series of LNA antisense oligonucleotides of diﬀerent
length (10- to 20-mers) were designed with 100%
sequence identity to the cynomolgus monkey and human
apoB mRNA sequences. The 10- to 16-mers were designed
to also have 100% sequence identity to mouse apoB
mRNA. (Genbank accession no.: NM_000384 and
NM_009693 for human and mouse apoB mRNA respect-
ively; the cynomolgus mRNA was sequenced in-house).
All oligonucleotides were designed as gap-mers containing
8–10 DNA nucleotides ﬂanked by 1–5 LNA nucleotides
at both ends with all internucleoside linkages phos-
phorothioated (Table 1).
All oligonucleotides were synthesized using standard
phosphoramidite protocols on an A ¨ KTA Oligopilot (GE
Healthcare) at 130mmol to 8mmol scales employing
custom made polystyrene primer supports. The DNA
monomers were obtained from Proligo (Sigma-Aldrich)
and the LNA monomers and solid support were
produced by Santaris Pharma (commercially available
from Exiqon, Denmark). After synthesis, the oligonucleo-
tides were cleaved from the support using aqueous
ammonia at 65 C overnight. The oligonucleotides were
puriﬁed by ion exchange and desalted using a Millipore-
membrane and were ﬁnally characterized by LC-MS
(Reverse phase and ESI-MS).
Melting temperature of LNA oligonucleotide/RNA
duplexes (Tm)
The binding aﬃnity of the LNA oligonucleotides,
determined as the melting temperature (Tm), was
measured against complementary RNA sequences as
described in Frieden et al. (12). In brief, the LNA oligo-
nucleotide and the complementary RNA was dissolved in
RNase free water and mixed with Tm-buﬀer (200mM
NaCl, 0.2mM EDTA, 20mM Na-phosphate, pH 7.0).
The solution was heated to 95 C for 3min and the oligo-
nucleotides were allowed to anneal at room temperature
for 30min. The duplex Tm values were measured on a
Lambda 25 UV/VIS Spectrophotometer equipped with a
Peltier temperature programmer (PTP6) using PE
Templab software (PerkinElmer). The temperature was
increased from 20 Ct o9 5  C and then down to 25 Ca t
1 C/min, and the absorption was recorded at 260nm every
minute. The ﬁrst derivative and the local maximums of
both the melting and annealing were used to assess the
duplex melting temperatures.
Cell culturing and transfections
Huh-7 cells (obtained from ECACC) were maintained in
complete medium consisting of DMEM (D5671, Sigma-
Aldrich), 2mM GlutaMAX (Invitrogen), 1xNEAA
(Invitrogen), 10% FBS (Biochrom AG) and 25mg/ml
Gentamicin (Sigma-Aldrich) at 37 C, 5% CO2.
Transfections were performed in 96-well plates (Nunc)
using a ﬁnal oligonucleotide concentration of 0–20nM.
A total of 7500 cells per well were seeded the day before
transfection. At the time of transfection, the medium was
changed to 80ml OptiMEM (Invitrogen) containing
2.5mg/ml Lipofectamine 2000 (Invitrogen) per well.
After 7–10min at room temperature, 20ml OptiMEM con-
taining oligonucleotide or saline was added. The cells were
incubated with the transfection mix for 4h, whereafter
medium was changed to complete medium and cells
were incubated for an additional 20h. Complementary
DNA was generated directly from each sample using the
TaqMan Gene Expression Cells-to-Ct kit (Applied
Biosystems) according to the manufacturer’s instructions.
Mouse studies
Inbred C57BL/6J female mice were obtained from
Taconic (Denmark) and fed ad libitum with a commer-
cially pelleted mouse diet (altromin no 1324, Gentofte,
Denmark) containing 4wt% fat. The animal facility was
illuminated to give a cycle of 12h light and 12h darkness.
Table 1. In vitro properties of oligonucleotides
Oligonucleotides
Oligonucleotide
a Length Tm versus
RNA ( C)
IC50 in
Huh-7
cells (nM)
50-TTCAGcattggtattCAGTG-30 20-mer 77 5.0±1.2
50-CAGcattggtatTCAg-30 16-mer 63 2.7±1.3
50-CAGcattggtatTCA-30 15-mer 60 0.5±1.3
50-AGCattggtatTCA-30 14-mer 61 0.2±1.2
50-GCattggtatTCA-30 13-mer 57 0.2±1.3
50-GCattggtatTC-30 12-mer 53 0.4±1.4
50-CattggtatT-30 10-mer 44 ND
50-gcattggtattc-30 12-mer PS 34 ND
aGap-mer oligonucleotides with LNA (capital) and DNA (plain font).
All internucleoside linkages are phosphorothioated. Melting tempera-
tures (Tm) of LNA oligonucleotides were measured against complemen-
tary RNA. ApoB mRNA (normalized to GAPDH) IC50 values were
determined from three independent experiments (±SD).
Non-detectable IC50 values, due to low potency, marked ND.
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LNA oligonucleotides were administered to the mice by
tail vein injection (i.v.) based upon body weight. All LNA
oligonucleotides were formulated in saline which was also
used as the control. The LNA oligonucleotides were ad-
ministered at 0.5–25mg/kg/dose. Retro-orbital sinus
blood was collected in S-monovette Serum-Gel vials
(Sarstedt) for serum preparation. At the time of sacriﬁce,
mice were anesthetized (70% CO2/30% O2) before blood
sampling and cervical dislocation was performed after
which livers and kidneys were collected in RNA-later
(Sigma-Aldrich) or snap frozen in liquid nitrogen. All
mouse experiments were performed according to the prin-
ciples stated in the Danish law on animal experiments, and
were approved by the Danish National Committee for
Animal Experiments, Ministry of Justice, Denmark.
Oligonucleotide content in tissue
Sample and standard preparation. Tissue samples(100mg)
were collected in 2ml Eppendorf tubes and kept on dry
ice. Extraction buﬀer 500ml [0.5% Igepal CA-630
(Sigma-Aldrich), 25mM Tris pH 8.0, 25mM EDTA,
100mM NaCl, pH 8.0] containing proteinase K (1mg/
ml) (Sigma-Aldrich P4850) and two tungsten carbide
beads (3mm) were added. The samples were homogenized
mechanically by a Retsch MM300 (8min at 25 revolutions
per seconds) and homogenates were incubated overnight
at 37 C. Control tissue from untreated animals were
spiked with the relevant oligonucleotides at 5–250mg/g
tissue and treated as described for the samples above.
Extraction of samples, standard and QC-samples. One
milliliter phenol–chloroform–isoamyl alcohol [25:24:1(v/
v/v)], saturated with 10M Tris, pH 8.0, and 1mM
EDTA (Sigma P2069) was added to each tissue samples
and vortexed for 5min. Phase separation was achieved by
centrifugation at 4000g for 15min. The aqueous phase
(upper-phase) was diluted 100 times. These dilutions
were kept at 4 C and were stable for up to 2 weeks.
Oligonucleotide content determination by ELISA (13-
mer). Streptavidin-coated strips (Immobilizer
Streptavidin LockWell module plate, Nunc) were washed
three times in 300ml5   SSCT buﬀer (750mM NaCl,
75mM sodium citrate, 0.05% Tween-20, pH 7.0). Each
well was incubated for 30min at room temperature
under gentle agitation with 100ml of a 0.02mM solution
of biotinylated capture probe (6-mer fully LNA-modiﬁed
phosphodiester oligonucleotide complementary to the
50-end of the 13-mer) in 5  SSCT buﬀer. The wells were
aspirated and washed three times with 300mlo f2  SSCT
buﬀer (300mM NaCl, 30mM sodium citrate, 0.05%
Tween-20, pH 7.0). One hundred microliters of the ex-
tracted and diluted oligonucleotide samples (pmol range)
were added to the wells, which were agitated at room tem-
perature for 0.5h. The wells were aspirated and washed
three times with 300mlo f2   SSCT buﬀer. One hundred
microliters of a 0.025mM solution of a 50-digitoxinated
conjugated (Dig) detection probe (5  SSCT buﬀer with
7-mer fully LNA modiﬁed phosphorodiester
oligonucleotide, complementary to the 30-end of the
13-mer) was added to each well and incubated for 1h at
room temperature under gentle agitation. The wells were
aspirated and washed three times with 300mlo f2   SSCT
buﬀer. One hundred microliters of anti-Dig-POD Fab
fragments (Roche Applied Science) diluted 1:4000 in
PBS containing 0.05% Tween-20 (pH 7.2) were added to
each well and incubated for 1h at room temperature
under gentle agitation. The wells were aspirated and
washed three times with 300mlo f2   SSCT buﬀer. One
hundred microliters of substrate solution (TMB +
Substrate-Chromogen, Dako) was added to each well
and incubated for 3–5min at room temperature under
gentle agitation, after which the incubation was stopped
by addition of sulphuric acid (100ml, 0.5M). The intensity
of the color development was measured spectrophotomet-
rically at 450nm, and the test samples were referenced
against the standard samples.
Cholesterol analysis
Serum was analyzed for total cholesterol using ABX
Pentra Cholesterol CP (Horiba ABX Diagnostics) accord-
ing to the manufacturer’s instructions. The cholesterol
content in serum lipoprotein classes was determined in
fractions separated by ultracentrifugation. The density of
the serum samples was adjusted to 1.067g/ml by addition
of NaBr, and the samples were then centrifuged for 4h at
100000r.p.m. in an Optima MAX table top ultracentri-
fuge using a TLA-100 rotor (Beckman Coulter). The top
(non-HDL fraction, mainly VLDL+LDL lipoproteins)
and bottom (HDL) fractions were isolated and analyzed
for total cholesterol content using the ABX Pentra
Cholesterol CP according to the manufacturer’s
instructions.
Liver enzyme ALT
The activity of alanine-aminotransferase (ALT) in mouse
serum was determined using an enzymatic ALT assay
(Horiba ABX Diagnostics) according to the manufactur-
er’s instructions adjusted to 96-well format. Data were
correlated to a 2-fold diluted standard curve generated
from an ABX Pentra MultiCal solution. The results
were presented as ALT activity in units/liter.
Quantitative whole-body autoradiography
35S was incorporated at the ultimate 50-phosphate position
of the 12- and 16-mer using a slightly modiﬁed version of a
standard protocol (13) where only carbon disulphide was
exchanged with carbon tetrachloride to eliminate
thio-oxidation of the ultimate 50-phosphite with the
solvent (carbon disulphide). After chromatographic puri-
ﬁcation the
35S-labeled oligonucleotides were administered
intravenously by tail vein injection to inbred C57BL/6J
female mice (Taconic, Denmark) at 9.2mg/kg for the
12-mer and 14.7mg/kg for the 16-mer. Individual mice
were sacriﬁced at 5min, 15min, 1h, 4h, 2 days, 7 days
and 21 days after injection of each oligonucleotide. Mice
were snap-frozen and sectioned sagittally for whole-body
autoradiography, as described by Ullberg (1977 and 1982;
14,15). Twenty micrometer sections were cut at diﬀerent
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24h. Sections together with calibration sets of
whole-blood solutions of the
35S-labeled oligonucleotide
were chosen for phosphor imaging analysis to best repre-
sent the tissues and organs of interest. Following
exposure, the imaging plates were scanned and the radio-
active content of the tissues and organs from the
radioluminograms were quantiﬁed by AIDA software
image analysis (Raytest, Germany). Area under the
curve (AUC) values (nCi h/mg tissue) were determined
and normalized to the speciﬁc radioactivity of each dose
(nCi/g animal weight).
Non-human primate study
Cynomolgus monkeys (30–52 months old) had access
to an expanded complete commercial primate diet
[100g/animal/day special diet services: OWN (E) short
SQC]. The animals (three males and three females per
dose level) received a 5min i.v. infusion of either saline
or the 13-mer at 2, 8 or 32mg/kg. A total of ﬁve admin-
istrations were given at days 0, 7, 14, 21 and 28. Blood
samples were collected from the femoral veins 10 days
before the ﬁrst administration (Day 10) and once a
week during the experiment (at Days 7, 14, 21 and 28)
prior to the subsequent dose. The animals were fasted
for at least 16h before sampling. Blood samples were
analyzed for ALT, serum apoB protein and serum choles-
terol (LDL and HDL cholesterol levels) by automated
analyzer using commercially available kits (Randox
Laboratories). The animals were sacriﬁced 24h after the
last infusion (Day 29). In the two highest dosing groups,
additional animals were included which after the last
infusion were left treatment-free for an additional 7
weeks. Blood was collected from these animals at days
35, 42, 56, 70 and 77 after the ﬁrst administration of oligo-
nucleotide. These animals were sacriﬁced at the end of the
treatment-free period (Day 77). Liver tissue was collected
in RNAlater or snap frozen in liquid nitrogen.
The cynomolgus monkey study was a part of our
clinical program and was conducted by a certiﬁed
contract organization (AAALAC accredited and
approved by the National Ministry of Agriculture) in ac-
cordance with the testing facility’s standard operating
procedure.
Quantitative PCR
Total RNA was extracted from tissue homogenates using
the RNeasy mini kit (Qiagen) according to the manufac-
turer’s instructions. First strand cDNA was generated
from total RNA by a reverse transcription reaction
using random decamers, 0.5mg total RNA, and the
M-MLV RT enzyme (Ambion), according to manufactur-
er’s instructions. mRNA quantiﬁcation of selected genes
was carried out using commercially available TaqMan
assays (Applied Biosystems). An applied Biosystems
7500Fast real-time PCR instrument was used for ampliﬁ-
cation. Data were analyzed and quantiﬁed using 7500Fast
SDS software. ApoB mRNA levels were normalized to
GAPDH or b-actin mRNA and presented relative to
saline control.
Histopathology
Mouse liver samples were cryosectioned for Oil Red O
staining and formalin-ﬁxed followed by cryosectioning
before hematoxylin and eosin staining in accordance
with previously published method by Moewis (16). The
Oil Red O staining was quantiﬁed using an image
analysis system (Leica Q500, Cambridge, UK) and the
percentage of Oil Red O staining calculated as area of
Oil Red O staining relative to total analyzed area.
Statistical analysis
Statistical analysis was performed using one-way ANOVA
with Bonferroni’s Multiple Comparison Test as post test
to determine the exact nature of the diﬀerences if the data
followed a Gaussian distribution. Otherwise, the non-
parametric Kruskal Wallis test with Dunn’s Multiple
Comparison test was used as a post test. P<0.05 was
considered to be of statistical signiﬁcance. The
GraphPad Prism version 4.03 was used for the statistical
analysis of data from the mouse experiments and the
Provantis data acquisition system was used to analyze
the primate data. The primate pharmacodynamic data
(serum apoB mRNA and protein versus oligonucleotide
concentration in liver) were analyzed using an inhibitory
eﬀect Emax model (model 103) in the WinNonlin program
(version 5.2.1; Pharsight Corporation).
RESULTS
In vitro properties of LNA oligonucleotides
The target aﬃnity of the LNA oligonucleotides was
measured Tm determined against the complementary
RNA sequences. The highest Tm was found for the
20-mer (77 C), with Tm decreasing as length and LNA
content was reduced (Table 1).
The Huh-7 human hepatoma cell line, which expresses
high levels of apoB mRNA, was used to evaluate the RNA
silencing properties of the oligonucleotides employing
standard transfection procedures. The 15-, 14-, 13- and
12-mer LNA oligonucleotides all potently reduced apoB
mRNA expression in a dose-dependent manner and with
essentially identical IC50 values ( 0.5nM). Molecules
below the 12-mer size, i.e. the 10-mer LNA oligonucleo-
tide, did not induce any detectable degree of target inhib-
ition. Above the 15-mer size, i.e. the 16- and 20-mer, target
inhibition decreased with increasing length (IC50 values of
the 16-mer and 20-mer at 2.7nM and 5nM, respectively;
Table 1), despite the fact that target aﬃnity increased. The
12-mer phosphorothioate without LNA nucleotides did
not reduce the expression of apoB mRNA at the concen-
trations used in this experiment.
Potency assessment in mice
The 12- to 16-mer LNA oligonucleotides were formulated
in saline and dosed at 5.0mg/kg i.v. on three successive
days in mice that were subsequently sacriﬁced 24h after
the last dose. All oligonucleotides reduced the expression
of apoB mRNA in the liver, and this correlated with a
decrease in the levels of total serum cholesterol at the
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13-mer, were found to be the most potent, resulting in
 80–90% reduction in both apoB mRNA and total
serum cholesterol relative to the saline control. In com-
parison, the 16-mer produced only a 16% reduction in
apoB mRNA and a 35% reduction in total serum choles-
terol (Table 2). The reductions in total cholesterol were
primarily due to a reduction in non-HDL cholesterol re-
sulting in an improved HDL/non-HDL ratio with all
tested oligonucleotides. No signiﬁcant changes were
observed in serum ALT with any of the oligonucleotides
(Table 2).
Mis-match speciﬁcity in mice
The expected advantage of shorter oligonucleotides to dis-
criminate between the correct and mismatched targets was
examined by comparing the potency of the 12-, 14- and
16-mers to that of single-base mismatched versions of
these oligonucleotides which created an A–A mis-match
to the apoB target in the oligonucleotide gap. This single
mismatch results in an 8.33%, 7.14 % and 6.25% theor-
etical mis-pairing for the 12-, 14- and 16-mer, respectively
and caused a decrease in the Tm values compared to the
fully matched LNA oligonucleotides. The relative change
in target aﬃnity (Tm) increased with the increased per-
centage mis-pairing; 16 C (12-mer), 10 C (14-mer) and
8 C (16-mer) conﬁrming the improved intrinsic speciﬁcity
for shorter oligonucleotides. The potency of the three sets
of matched/mis-matched oligonucleotides was evaluated
in vivo in mouse livers and kidneys. As the fully matched
LNA oligonucleotides was found to have diﬀerent
potencies (vide supra), the animals were dosed at 2.5, 5.0
and 25mg/kg for the 12-, 14- and 16-mer, respectively, to
establish a similar level of hepatic apoB mRNA reduction.
The mice were dosed on three successive days, and
sacriﬁced 24h after the last dose. In the liver, the perfect
matched LNA oligonucleotides exhibited an equal 75%
reduction of apoB mRNA, whereas none of the
mis-matched LNA oligonucleotides produced any eﬀect
(data not shown) thus preventing any conclusion on spe-
ciﬁcity versus length. In kidney, however, the mis-matched
oligonucleotides showed to be less potent as size decreased
an observation which was even further augmented by an
increased potency of the matched oligonucleotides
(Figure 1).
Quantitative whole-body autoradiography
To understand whether the diﬀerent potencies of the 12-
to 16-mer LNA oligonucleotides were the consequence of
diﬀerences in biodistribution or tissue half-life, the 12-mer
and the 16-mer LNA oligonucleotides were covalently
labeled at the 50-internucleoside bond with
35S, and
injected i.v. in mice at identical molar concentrations
[labeled LNA oligonucleotides are highly stable in
tissues, allowing a correlation between the presence of
radioactivity and intact oligonucleotide (11,17)]. Mice
were sacriﬁced at diﬀerent time points after dosing,
ranging from 5min to 21 days, snap-frozen, sectioned,
subjected to whole-body autoradiography, and quantiﬁed
by using whole-blood solutions of the
35S-labeled oligo-
nucleotides as reference standard. The two LNA oligo-
nucleotides exhibited a very similar distribution pattern
across diﬀerent tissues (Figure 2A and B). The highest
levels of radioactivity/oligonucleotide accumulation were
found in kidney cortex, liver, bone marrow, spleen, ovary,
uterus and adrenal cortex (Figure 2C). Furthermore, in
the liver, the distribution rate and peak value time were
similar for the two oligonucleotides, 75 nCi h/mg and 4h,
Table 2. In vivo potency of LNA oligonucleotides
Parameter LNA oligonucleotide
Saline 16-mer 15-mer 14-mer 13-mer 12-mer
ApoB mRNA in liver (% of saline group) 100±15
a 84±9
a,b 78±18
b 18±6
c 7±3
c 8±2
c
Total cholesterol in serum (mg/dl) 84±13
a 55±10
b 54±7
b 22±5
c 10±2
c 14±3
c
HDL/(non-HDL) ratio* 2±0
a 4±1
a,c 5±1
a,c 11±4
b 10±6
b,c 8±3
b,c
ALT in serum (U/L) 52±17 42±8 25±5 68±14 55±8 75±15
Mice were administered 5mg/kg LNA oligonucleotide i.v. on three successive days and sacriﬁced 24h after last dose. ApoB mRNA expression in
liver was normalized to GAPDH levels (in percent of saline control group). Absolute total serum cholesterol levels, lipoprotein fractions and ALT
were measured in serum.
a,b,cValues in the same row but with diﬀerent superscript letters are signiﬁcantly diﬀerent (P<0.05). *Values for non-HDL
(mainly VLDL+LDL) and HDL represent percent of total serum cholesterol recovered in the respective fraction after ultracentrifugation. Data
represents mean values ± SD, n=6.
Figure 1. Mismatch speciﬁcity in mice. Mice were administered
i.v. injections of saline, the 12-, 14- and 16-mer and their respective
one mismatch versions at 2.5, 5 and 25mg/kg, respectively on three
successive days and sacriﬁced 24h after last dose. Kidneys were
analyzed for apoB mRNA expression normalized to GAPDH (in
percent of saline control group). Data represent mean values ± SD,
n=5. MM indicates mismatch and PM perfect match. Tm values
represent the diﬀerence in Tm between PM and MM oligonucleotides
measured against RNA complementary to the perfect match
oligonucleotides.
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to be 9 days for the 12-mer and 14 days for the 16-mer.
Single dose studies in mice
To examine the pharmacological properties of a short
LNA oligonucleotide, the 13-mer was selected for
further in vivo studies. Mice were administered single i.v.
injections at 5, 10, 15, 20 or 25mg/kg and sacriﬁced 24 and
48h after dosing. The liver content of the 13-mer was
measured and found to correlate linearly with dose level
(R
2=0.88), at  0.7mg oligonucleotide/g liver for each
1.0mg/kg dosed (Figure 3A). The apoB mRNA expres-
sion reached maximum reduction at the dose levels 10–
15mg/kg at 24 and 48h after dosing (>83%, Figure 3B).
Higher doses of the oligonucleotide (resulting in higher
liver content), did not produce further signiﬁcant reduc-
tion in either the expression of the apoB mRNA or total
serum cholesterol 48h after dosing. The reduction in apoB
mRNA was rapid and preceded the eﬀect on total serum
cholesterol, which increased from 24 to 48h after dosing.
Thus, the maximum eﬀect in mice in this study was
reached at a dose of 10–15mg/kg, which corresponds to
an accumulation of 7–11mg of the 13-mer per gram of
liver.
The duration of eﬀect in mice was studied after single
i.v. injections of 0.5, 1.0, 2.5 and 5.0mg/kg of the 13-mer.
The mice were sacriﬁced 1, 3, 8, 16 and 32 days after
dosing. A single dose resulted in a rapid and dose-
dependent reduction of liver apoB mRNA expression
and total serum cholesterol (Figure 4). The lowest and
highest dose (0.5mg/kg and 5mg/kg), respectively,
resulted in a reduction in apoB mRNA expression of
47% (P<0.01) and 78% (P<0.001) and total serum chol-
esterol of 25% (P<0.05) and 52% (P<0.001) already
1day after dosing.
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Figure 3. Single dose in mice. Mice were administered a single i.v. in-
jection of 5, 10, 15, 20 and 25mg/kg of the 13-mer and sacriﬁced 24
and 48h after dosing. (A) The 13-mer oligonucleotide content was
measured in liver and presented as function of dose level at 24h
(crosses) and 48h (boxes) after dosing. The linear correlation
(R
2=0.88) showed oligonucleotide content of  0.7mg oligonucleo-
tide/g liver for each 1mg/kg administered. (B) Liver apoB mRNA ex-
pression (crosses) and serum total cholesterol (circles) were measured
for all dose levels 24h (solid line) and 48h (dashed line) after dosing.
Data are expressed as percentage of respectively, apoB mRNA and
serum total cholesterol in saline control and presented as mean
values±SD, n=5/dose level and time point. The apoB mRNA ex-
pression was normalized to the expression of GAPDH.
Figure 2. Quantitative whole-body autoradiography. Tissue distribu-
tion in mice of two
35S-labelled oligonucleotides, the 12- and 16-mer
(A and B, respectively), administered i.v. Individual mice were sacriﬁced
at 24h post-administration, snap-frozen and sectioned for whole-body
autoradiography. Following exposure the imaging plates were scanned,
tissues and organs intensity were quantiﬁed by image analyses. (C)
Area under the curve values normalized to the speciﬁc radioactivity
of the dose levels of 16-mer (dark bars) and 12-mer (white bars).
Nucleic Acids Research, 2010,Vol.38, No. 20 7105The eﬀect of a single dose was long lasting, and
correlated with the estimated elimination half-life of 9–
14 days determined for the 12- and 16-mer (vide supra).
At the highest dose (5.0mg/kg), hepatic apoB mRNA ex-
pression and total serum cholesterol were reduced by
 90%, 3 days after dosing (P<0.001), and the eﬀect
was still signiﬁcant after 3 weeks (Figure 4).
Multiple dose study in mice
The data from the single dose studies indicated that dosing
once weekly or biweekly would be suﬃcient to achieve
sustained and signiﬁcant reductions in serum cholesterol.
Accordingly, a multiple dose study was conducted in
which mice were dosed with the 13-mer either once
weekly (Group 1) or biweekly (Group 2) for a total of 7
weeks. In both groups, mice received the 13-mer i.v. at 1.0,
2.5 or 5.0mg/kg. The mice in Group 1 received a total of
seven doses, and the mice in Group 2 received a total of
four doses of each concentration. In both groups, serum
sampling for cholesterol analysis was conducted weekly
and immediately before administration of the next dose.
Livers were collected for apoB mRNA analysis at the end
of the study (Day 49), 1 week after the last dose.
Reductions in hepatic apoB mRNA levels at the end of
the study were  70%, 80% and 90% for dose levels 1.0,
2.5 and 5.0mg/kg, and were similar both in mice dosed
weekly and biweekly (data not shown).
These reductions in apoB mRNA expression were par-
alleled by a signiﬁcant decrease in apoB containing lipo-
proteins (non-HDL) throughout the study. At 1mg/kg
weekly dosing, non-HDL cholesterol levels were gradually
reduced throughout the dosing period, reaching  80%
reduction compared to saline control level at the end of
the experimental period (Figure 5A). The 2.5mg/kg
weekly dose further improved the eﬀect after the ﬁrst 2
weeks, and led to a  90% reduction in non-HDL levels
relative to saline control at the end of the study.
Consistent with the substantial activity of the 2.5mg/kg
dose, no further reduction in non-HDL cholesterol was
observed with the 5mg/kg dose. All three dose levels
also aﬀected HDL cholesterol levels, albeit signiﬁcantly
less (P<0.001) than the eﬀects on non-HDL cholesterol,
reaching 40–60% relative to saline levels at the end of the
study (Figure 5B).
Biweekly dosing produced a rather similar picture
between the three dose groups as weekly dosing,
although both the rate of reduction and maximum reduc-
tion at the end of the study was smaller on both measured
parameters, non-HDL (Figure 5C) and HDL cholesterol
(Figure 5D). Similar to what was observed in the weekly
dosing group the eﬀect on HDL in biweekly dosing was
also signiﬁcantly less than the eﬀect on non-HDL
(P<0.001). Overall, the HDL/non-HDL ratios at the
end of the study were identical for the two diﬀerent dose
regimens,  4-fold increase compared to saline treated
animals.
Multiple dose study in non-human primates
Wild-type mice have at least 70% of their serum choles-
terol carried as part of HDL particles, whereas
cynomolgus monkeys have almost equal distribution
between HDL and non-HDL cholesterol (18). Thus,
cynomolgus monkeys more closely resemble humans that
have  70% of serum cholesterol in LDL particles (19).
Male and female cynomolgus monkeys were therefore
used in a multiple dose study, where they were dosed i.v.
with the 13-mer once a week for 4 weeks (a total of 5
doses). The dose levels were 2, 8 and 32mg/kg/week. A
recovery group from the saline and the two highest dose
level groups were kept treatment-free for an additional
period of 7 weeks.
Following treatment with the 13-mer, LDL cholesterol
levels were reduced in a dose-dependent manner. Close to
maximal eﬀect was reached already after the second ad-
ministration where the dose levels 2, 8 and 32mg/kg/week
resulted in  45%, 70% and 90% reduction in LDL chol-
esterol, respectively, and the LDL cholesterol remained
hereafter at similar levels for the rest of the treatment
period in all dose groups, relative to saline (Figure 6A).
In the mid- and high-dose groups, LDL cholesterol was
also signiﬁcantly reduced throughout the recovery phase,
with signiﬁcant reductions still evident 7 weeks after last
dose (Figure 6A). The LDL cholesterol levels correlated
Figure 4. Duration of eﬀect in mice. Mice were administered a single
i.v. injection of saline (diamonds) or 13-mer at 0.5 (white boxes), 1
(dark boxes), 2.5 (crosses) and 5mg/kg (circles). Livers were analyzed
for (A) apoB mRNA expression normalized to GAPDH and (B) serum
total cholesterol levels (both in percent of control groups) at days 1, 3,
8, 16 and 32 after administration. (Data represent mean values±SD,
n=5).
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correlation coeﬃcient R
2=0.94 (data not shown).
During the treatment period, HDL cholesterol was also
aﬀected in a dose-dependent manner, albeit signiﬁcantly
less than non-HDL, and only marginally—if at all—at the
lowest dose (Figure 6B). HDL cholesterol remained
reduced in the high dose group during the 7 weeks of
recovery whereas it returned to the saline control level in
the mid-dose group (Figure 6B).
Liver apoB mRNA expression was determined for all
three dose groups at the end of the treatment period
(Day 29), and the end of the recovery period (Day 77)
for the mid- and high-dose groups. ApoB mRNA was
reduced in a dose-dependent manner, reaching a 90%
reduction in the high-dose group (Figure 6C) at the
end of dosing, where also LDL cholesterol was reduced
by  90% (vide supra). ApoB mRNA levels increased
during the recovery period but were still reduced by
35% and 70% in the mid- and high-dose groups, respect-
ively at Day 77.
The amount of LNA oligonucleotide in liver was
measured in all animals at the end of the dosing period,
and was found to correlate closely with the reduction in
both apoB mRNA and serum protein (Figure 7). The best
estimated non-linear regression ﬁt appeared to follow the
inhibitory eﬀect Emax model (R
2=0.90 for mRNA and
R
2=0.88 for protein). According to this ﬁt, a 50% reduc-
tion in apoB mRNA and protein was obtained at a liver
concentration of the LNA oligonucleotide of  10 and
15mg/g liver, respectively.
Although small ﬂuctuations were observed in serum
ALT levels for the monkeys in the 32mg/kg/week group,
no statistically signiﬁcant changes were recorded for any
of the groups throughout the entire experimental period
(Figure 6D).
DISCUSSION
LNA has been used extensively to inhibit RNA expres-
sion. In addition, LNA gapmers have been described as
a highly potent class of oligonucleotides for mRNA inhib-
ition (11,20). These molecules are usually designed with a
central DNA segment (6–10 nucleotides) that is ﬂanked
at each molecular terminus by 2–4 LNA nucleotides.
This design is particularly potent for three synergistic
reasons: the LNA nucleotides provide a high binding
aﬃnity for the target; the central DNA region triggers
RNase H cleavage activity; and since all the phosphate
groups are thioated, the gapmer is highly nuclease resist-
ant. All these basic properties of LNA oligonucleotides
have been extensively commented on in the literature
(17,21–31).
We demonstrate here that LNA oligonucleotides, in
length as short as 12nt, exhibit high antisense activity in
both liver and kidney of mice (32) and non-human
primates. The data further show that both aﬃnity and
size are major determinants for the potency of LNA oligo-
nucleotides. The importance of aﬃnity is illustrated by the
fact that the 12-mer LNA oligonucleotide (Tm=53  C),
exhibited an IC50 value of 0.4nM, whereas the
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Figure 5. Multiple dosing in mice. Mice were administered i.v. injections weekly (group 1, left panel) or biweekly (group 2, right panel) for 49 days
with either saline (diamonds) or the 13-mer at 1 (dark boxes), 2.5 (crosses) or 5mg/kg (circles) (arrows on bottom ﬁgure indicates dosing days).
Serum was analyzed for non-HDL cholesterol (mainly VLDL+LDL) (A and C) and HDL cholesterol (B and D) at 0, 14 and 49 days after ﬁrst
administration. (Data represent mean values ± SD, n=7).
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oligonucleotide (Tm=34  C) had no eﬀect. The fact that
potency correlates positively with aﬃnity for
iso-sequential oligonucleotides has also been described
for other targets (1,2). The 10-mer LNA oligonucleotide
had a much reduced aﬃnity (Tm=44  C), compared to the
12-mer, which is likely the reason that it did not exhibit
any activity.
The importance of size is illustrated by the fact that the
longer oligonucleotides (>14-mer) did not exhibit higher
potencies despite their inherent higher aﬃnities. This
pattern was augmented in vivo where potency decreased
signiﬁcantly with increasing size, illustrated by the fact
that the 12- and 13-mers were approximately 11 times
more potent than the 16-mer.
Both the 12-mer and the 16-mer LNA oligonucleotides
accumulated identically in the target organs (liver and
kidney) over time in mice, so the diﬀerences in potencies
between the diﬀerently sized oligonucleotides cannot be
explained by distribution diﬀerences. Neither can the
potency diﬀerences be explained by diﬀerences in tissue
half-lives which appeared to be longer for the 16-mer
compared to the 12-mer.
Taken together, these diﬀerences might be explained by
the presence of a ‘threshold aﬃnity’ that an oligonucleo-
tide must achieve in order to exhibit high potency, and
beyond which further increase in aﬃnity will not necessar-
ily correlate with additional potency. At the same time, the
data also indicate that there is a ‘length penalty’ that
reduces potency and which not necessarily is compensated
by increased aﬃnity.
Although only scarcely experimentally supported at this
time, this ‘length penalty’ could be linked to protein
binding. Phosphorothioate oligonucleotides are known
to bind several plasma proteins in a length-dependent
manner (33) so the increased potency of shorter LNA
oligonucleotides could be the result of faster and more
eﬃcient intracellular availability for target hybridiza-
tion—provided by reduced protein binding. Contrary to
this, longer oligonucleotides would bind proteins more
strongly rendering them less eﬃcient for target hybridiza-
tion. Finally, oligonucleotides with more than 15
phosphorothioate linkages have been shown to inhibit
the activity of human RNase H (34) suggesting that this
could be another contributing factor to the observed
‘length penalty’.
Figure 6. Multiple dosing in non-human primates. Cynomolgus monkeys were administered i.v. injections of the either saline (diamonds) or the
13-mer at 2 (dark boxes), 8 (crosses) or 32 (circles) mg/kg once a week for 28 days (arrows on ﬁgures indicates dosing days). Serum was sampled 10
days prior to ﬁrst administration (Day 10) and every week from the ﬁrst administration. LDL cholesterol (A), HDL cholesterol (B), ALT activity
(D) in serum relative to saline control group was measured (±SD, n=10). A subset of animals at the 8 and 32mg/kg dose levels were kept
treatment-free for an additional seven week period (n=4). ApoB mRNA expression in liver normalized to b-actin and relative to saline control
group (C) at the end of the treatment period (Day 29, ±SD, n=6) and at the end of the treatment-free period (Day 77, ±SD, n=4).
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nucleotides can be taken up by cells in culture by simply
adding the LNA oligonucleotides without transfection
reagents to the medium, a process termed gymnotic
delivery. The data indicated that in cell cultures under
gymnotic delivery shorter LNA oligonucleotides
appeared to act faster and be most potent. Furthermore,
it was reported that the potency/length relation found
in vitro correlated with the in vivo outcome (35). These
data indicated that in vitro results obtained under
gymnotic delivery may be more predictive, compared to
classical transfection assays, for the in vivo outcome (35).
As an extension of this work with apoB targeting oligo-
nucleotides (35), a study in cell cultures under gymnotic
delivery using Bcl-2 targeting oligonucleotides was con-
ducted (Supplementary Data). In this study, eight LNA
gapmers were tested, of which seven were truncated from a
22-mer base sequence. It appeared that all three 12-mers
were signiﬁcantly more potent inhibitors of Bcl-2
compared to the longer ones (>14-mers), and in parallel
to the data described above, the onset of action of the
shortmers was faster. Work to resolve this mechanism is
currently ongoing in our laboratories.
Our data also indicate that short LNA oligonucleotides
are better at discriminating between matched and
mis-matched target sequences. The Tm (Tm matched-
Tm mis-matched) increased as the LNA oligonucleotide
size decreased, and that correlated in vivo with higher
target speciﬁcity (Figure 1). This discrimination was
observed in kidney which accumulates the highest
amount of oligonucleotide per gram tissue, allowing the
mis-matched LNA oligonucleotides to reach concentra-
tions that could exhibit some activity. In the liver, none
of the mismatched LNA oligonucleotides showed any
activity at the doses employed in the study thus preventing
any conclusion on speciﬁcity versus length.
The present discussion is based on data obtained with a
single target (apoB) and a relatively small number of
oligonucleotides. Thus, it obviously does not allow for
any generalization as to how aﬃnity and size will aﬀect
the potency and speciﬁcity of LNA oligonucleotides
against other targets. It merely points to the fact that
oligonucleotide size as a parameter is important for
potency, and furthermore, the data illustrate that in
order to exploit that parameter for making better anti-
sense oligonucleotides—with higher potency and speciﬁ-
city—a high aﬃnity chemical component like LNA has to
be used.
Inhibiting apoB mRNA serves as a new and potentially
powerful strategy for cholesterol lowering therapies
(7,36–38). With this in mind, the present study was also
directed at understanding what sort of potency could be
achieved in mice, and more importantly, in non-human
primates with appropriately designed LNA oligonucleo-
tides. The most intensively studied LNA oligonucleotide
was the 13-mer, which in mice provided a very potent and
long lasting reduction in all the parameters studied. In
fact, in mice, a single dose of 0.5mg/kg of the 13-mer
administered i.v. without any formulation, reduced apoB
mRNA by 47% and total serum cholesterol by 25% one
day after dosing, and with activity still being signiﬁcant
one week after. Consistent with these characteristics,
dosing the 13-mer at 1mg/kg biweekly produced a reduc-
tion in non-HDL cholesterol of  75% at the end of a
7-week study. In comparison, Crooke et al. (3) reported
that an 20-mer 20-MOE oligonucleotide, dosed twice
weekly for 4 weeks at 50mg/kg, was able to achieve a
60% reduction in total serum cholesterol in mice at the
end of the study.
Reducing the expression of hepatic apoB prevents liver
secretion of VLDL particles. This gives rise to lipid accu-
mulation in the liver (8,39) and elevations of liver
enzymes, which has been observed after apoB inhibition
employing siRNA (4). Consistent with these reports, we
observed mild accumulation (up to 6–7% of total liver
weight) of neutral lipids in our multiple dose study in
mice, and this was associated with mild increases in
ALT (up to 3-fold; data not shown). Dosing three times
5mg/kg did not cause any signiﬁcant increase in ALT
(Table 1).
In monkeys where the HDL/LDL ratio is closer to the
ratio in human, the 13-mer also demonstrated strong
Figure 7. Oligonucleotide content in liver relative to apoB levels in
cynomolgus monkeys. The liver tissue content of the 13-mer was
measured in all samples from the multiple dosing study in cynomolgus
monkeys after the end of the treatment period (Day 29). Data are
presented relative to apoB mRNA expression in liver (A) and serum
apoB protein levels (B). Best estimated Emax ﬁt curves are plotted with
R
2=0.88 and R
2=0.90 for mRNA and protein levels, respectively.
Nucleic Acids Research, 2010,Vol.38, No. 20 7109potency and long lasting eﬀect. The low-dose group
(2.0mg/kg, administered weekly for 4 weeks) achieved
an oligonucleotide concentration in liver of  10mg oligo-
nucleotide/g liver, and produced a reduction in non-HDL
cholesterol of 45%. Notably, this dose level did not sig-
niﬁcantly aﬀect HDL which only was aﬀected at the
higher doses, indicating that dose regimens can be found
that will potently and exclusively aﬀect the non-HDL
components. At this dose level, there were no elevations
in liver enzymes and no accumulation of liver lipids (data
not shown).
Reduction of apoB mRNA expression in monkeys with
a 20-mer 20-MOE oligonucleotide has previously been
reported (38). In this study, the 20-mer was dosed to
high-fat fed cynomolgus monkeys, at 35mg/kg twice a
week for 5 weeks (total of  385mg/kg), resulting in a
70% reduction in LDL-cholesterol. The EC50 for both
serum apoB protein and liver apoB mRNA was reported
to be reached at 300mg oligonucleotide/g liver compared
to the estimated EC50 of the 13-mer LNA oligonucleotide
of  10 and 15mg/g for apoB mRNA and apoB serum
protein, respectively (Figure 7).
In conclusion, we have shown that oligonucleotide
length as a parameter can be exploited to improve the
design of antisense oligonucleotides. We have illustrated
that in order to design potent oligonucleotides it is import-
ant to balance target aﬃnity against oligonucleotide
length, and that the most potent oligonucleotides are
likely among the shortest exhibiting the sequence depend-
ent threshold aﬃnity. The use of LNA provides the target
aﬃnity needed for the design of shorter oligonucleotides
with high in vivo potency and therapeutic potential. Such
molecules delivered systemically without delivery vehicles
were here demonstrated to potently down-regulate apoB
mRNA in liver and lower serum non-HDL cholesterol in
mice and non-human primates.
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